423 – The effects of portulaca oleracea L(purslane) on psychologic symptoms of schizophrenic patients

Abstract

Background:Despite the availability of an ever-expanding range of typical and atypical antipsychotics, a substantial proportion of patients with schizophrenia show a partial or total lack of response to antipsychotic mono therapy. This study was done to evaluate the effect of purslane on psychologic symptoms of schizophrenic patients.Materials and methods:This randomized clinical trial study was carried out on 60 chronic schizophrenic patients in Sina hospital Shahrekord, Iran during 2011-12. Subjects were randomly divided into intervention and control groups. The control group received Risperidone up to 6mg/day and Biperiden 4mg/day for 8 weeks. The Patients in interventional group received 1gr extract of purslane daily with the same regimen for 8 weeks. The scales for assessment of positive symptoms (SAPS) and assessment of negative symptoms (SANS) were recorded in prior and 8th weeks. In addition, CRP and MDA level of patients were assessed in two stage of study.Results:At the end of study, the mean score of positive symptoms were 47.93±18.56 and 57.1±14.83 in intervention and control groups, respectively (P< 0.05), and the mean score of negative symptoms were 40.83±11.03 and 46.13± 9.34 (P< 0.05).The CRP levels of patients in intervention and control groups were .53±.55 and 1.72±.73 at 8 week respectively (P< .05) and the MDA levels were 3.25±1.25 and 5.43± 1.76 respectively (P< .05).Conclusion:According to findings of this study, the use of purslane as an adjunct to Respridone can improve psychological condition of chronic schizophrenic patients and decrease MDA and CRP levels of them.

Effects of purslane supplementation on C‐reactive protein levels and biomarkers of oxidative stress as marks for metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trials

“…Of those, four studies were discarded for the following reasons: (a) non‐RCT design, (b) studies not included data of interest or not provided sufficient data for the outcomes, and (c) irrelevant for the meta‐analysis. Finally, 10 studies (Bedakhanian, Entezari, Ghanadian, Askari, & Maracy, 2017; Dehghan et al, 2016; Fakoori Jouibari, Farzanegi, & Barari, 2014; Farzanegi, 2014; Gheflati et al, 2019; Ghorbanian, Saberi, Azali Alamdari, Shokrollahi, & Mohammadi, 2019; Mohammadzadeh et al, 2016; Parvin, Farzaneh, Vardanjani, Goodarzi, & Nikfarjam, 2013; Rafiee Vardanjani et al, 2013; Zakizadeh et al, 2015) met the eligibility criteria and were included in the quantitative meta‐analysis. Four studies reported the CRP (Bedakhanian et al, 2017; Dehghan et al, 2016; Farzanegi, 2014; Parvin et al, 2013), five (Fakoori Jouibari et al, 2014; Gheflati et al, 2019; Ghorbanian et al, 2019; Rafiee Vardanjani et al, 2013; Zakizadeh et al, 2015), four (Gheflati et al, 2019; Ghorbanian et al, 2019; Mohammadzadeh et al, 2016; Zakizadeh et al, 2015), and three (Fakoori Jouibari et al, 2014; Ghorbanian et al, 2019; Mohammadzadeh et al, 2016) articles reported MDA, TAC, and SOD, respectively, as outcomes.…”

“…The supplementation was based on purslane powder and extract, with daily recommended dose varying between 60 mg extract and 10 g powder. The design of all studies was parallel and the sample size ranged from 14 to 98 individuals in which the clinical conditions involved: metabolic syndrome (Bedakhanian et al, 2017), schizophrenia (Parvin et al, 2013; Rafiee Vardanjani et al, 2013), aphthous stomatitis (Mohammadzadeh et al, 2016), nonalcoholic fatty liver disease (Gheflati et al, 2019), type 2 diabetes (Dehghan et al, 2016; Fakoori Jouibari et al, 2014; Farzanegi, 2014; Zakizadeh et al, 2015), and healthy subjects with overweight or obesity (Ghorbanian et al, 2019). The mean age of participants was 42.9 years old.…”

“…The mean age of participants was 42.9 years old. Five articles were conducted on both genders (Gheflati et al, 2019; Mohammadzadeh et al, 2016; Parvin et al, 2013; Rafiee Vardanjani et al, 2013; Zakizadeh et al, 2015) and four (Dehghan et al, 2016; Fakoori Jouibari et al, 2014; Farzanegi, 2014; Ghorbanian et al, 2019) and one study (Bedakhanian et al, 2017) performed on women and men, respectively. Table S1 shows the results of the quality assessment of eligible studies.…”

“…However, it is fundamental to mention that our analysis for CRP levels was obtained using only four studies (Bedakhanian et al, 2017;Dehghan et al, 2016;Farzanegi, 2014;Parvin et al, 2013), with significant heterogeneity detected (I 2 = 87.4%, p = .001).…”

“…Characteristics of the pooled studies are presented in Table 2. All schizophrenia (Parvin et al, 2013;Rafiee Vardanjani et al, 2013), aphthous stomatitis (Mohammadzadeh et al, 2016), nonalcoholic fatty liver disease (Gheflati et al, 2019), type 2 diabetes (Dehghan et al, 2016;Fakoori Jouibari et al, 2014;Farzanegi, 2014;Zakizadeh et al, 2015), and healthy subjects with overweight or obesity (Ghorbanian et al, 2019). The mean age of participants was 42.9 years old.…”